Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
Kuldeep Singh Bhadauria, Senior Brand Lead of Hematology, Rare Disease and Immunology at Takeda, shared a post on LinkedIn:
“Hemophilia Care Transition…..
Haemophilia care in India is undergoing a profound transition due to significant focus of Innovation hubs shifts to Rare Diseases Like Roche, Novo Nordisk, Sanofi , Pfizer.
The Convergence of low-dose prophylaxis (LDP), non-factor therapies such as Emicizumab and Concizumab, Extended half-life products and the emergence of gene therapy is reshaping the treatment paradigm and creating Unprecedented Possibilities for improving patient outcomes.
The market is therefore transitioning from a predominantly on-demand, factor-replacement model toward proactive, prophylaxis-led and increasingly factor-independent care.
However, India’s progress remains uneven. While pockets of excellence exist across leading haemophilia centres, significant gaps still persist in diagnosis, prophylaxis penetration, affordability, access, laboratory capability and continuity of care.
The Next Phase of haemophilia care in India……
will be defined not only by innovation, but by our ability to make innovation accessible and scalable.
Key opportunity pools
Haemophilia A
The largest opportunity pool, driven by the high prevalence of FVIII deficiency and rapid adoption of non-factor therapies.
Haemophilia B
A smaller patient population but a strategically attractive segment because of the limited non-factor treatment options historically available, creating potential for rebalancing therapies.
Inhibitors
A high-unmet-need segment with an estimated market of approximately ₹450 Cr, providing an important beachhead for novel haemostatic approaches
Winning Strategy is Creating a Ecosystem not just scaling brand alone..
The winning strategy will combine clinical differentiation, affordability, patient identification, government access, HFI engagement, laboratory readiness and real-world evidence.
Pateint Centricity, Hemophilia Federation India (HFI) is a critical stakeholder in the Indian haemophilia ecosystem.
Strong P3 (Public-Private-Patient group) collaboration will be Beach Head and winning equation to build sustainable and scalable ecosystem to expand Reach of Innovative care to million Hemophilics and improve QOL .
This equation will strengthen Healthy India objective.
Lets work together……”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!
-
Sep 28, 2026, 19:07Dhargam Aljebouri: AIHA Subclassification Research Presented at the 14th Iraqi Society of Hematology Conference
-
Sep 28, 2026, 19:02William Wallace: Your Cholesterol Test is Missing a Particle that May Matter More than the One it Measures
-
Sep 28, 2026, 18:57Indu Thakur: Honoring Sickle Warriors and Advancing Diverse Blood Donation at Sickle Ball 2026
-
Sep 28, 2026, 18:48Orly Leiva: Rethinking JAK Inhibitor Cardiovascular Safety in MPNs
-
Sep 28, 2026, 18:42Wael Saad: Honored to Be Part of Portal and Mesenteric Vein Thrombosis Session at CIRSE 2026
-
Sep 28, 2026, 18:35Alejandro González Veliz: The Unbroken Connection Between Heart and Brain
-
Sep 28, 2026, 16:43Scott Sutton: Community and Connection in Immune Thrombocytopenia
-
Sep 28, 2026, 16:24Pankti Solanki: ISBT Recognized JAMA as the 49th Human Blood Group System